Skip to Main Content

Glioblastoma is one of the deadliest cancers — an illness that responds to few treatment options, and often poorly. But a single case study that uses an experimental immunotherapy to treat these brain tumors might give oncologists a new way to approach the disease.

The therapy, called CAR-T, is controversial and has faced hurdles in clinical trials. It has shown great promise in treating blood cancers like leukemia and lymphoma — but has proven challenging in treating other forms of the disease, including solid tumors.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED
  • I would wonder whether the immune privileged nature of the brain contributes to the lack of serious side-effects? 

Comments are closed.